Real-world use of ceftolozane/tazobactam: a systematic literature review
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Real-world use of ceftolozane/tazobactam: a systematic literature review
Authors
Keywords
-
Journal
Antimicrobial Resistance and Infection Control
Volume 10, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-04-08
DOI
10.1186/s13756-021-00933-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Real-world experience with ceftolozane-tazobactam for multidrug-resistant gram-negative bacterial infections
- (2020) Sarah C.J. Jorgensen et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical Efficacy of Ceftolozane-Tazobactam Versus Other Active Agents for the Treatment of Bacteremia and Nosocomial Pneumonia due to Drug-Resistant Pseudomonas aeruginosa
- (2020) Antonio Vena et al. CLINICAL INFECTIOUS DISEASES
- Efficacy and safety of ceftolozane/tazobactam as therapeutic option for complicated skin and soft tissue infections by MDR/XDR Pseudomonas aeruginosa in patients with impaired renal function: a case series from a single-center experience
- (2020) A. R. Buonomo et al. INFECTION
- Clinical and Safety Evaluation of Continuously Infused Ceftolozane/Tazobactam in the Outpatient Setting
- (2020) Bruce M Jones et al. Open Forum Infectious Diseases
- Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study)
- (2020) Matteo Bassetti et al. Open Forum Infectious Diseases
- Clinical pharmacokinetics of ceftolozane and tazobactam in an obese patient receiving continuous venovenous haemodiafiltration: A patient case and literature review
- (2020) Ahmed Mahmoud et al. Journal of Global Antimicrobial Resistance
- Ceftolozane-tazobactam pharmacokinetics during extracorporeal membrane oxygenation in a lung transplant recipient
- (2019) Fabio Arena et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Use of continuous infusion ceftolozane–tazobactam with therapeutic drug monitoring in a patient with cystic fibrosis
- (2019) Sarah Elizabeth Davis et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Incremental clinical and economic burden of suspected respiratory infections due to multi-drug-resistant Pseudomonas aeruginosa in the United States
- (2019) Y.P. Tabak et al. JOURNAL OF HOSPITAL INFECTION
- Bacteriophage Therapy of Ventilator-associated Pneumonia and Empyema caused by Pseudomonas aeruginosa
- (2019) Susan Maddocks et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial
- (2019) Marin H Kollef et al. LANCET INFECTIOUS DISEASES
- Higher MICs (>2 mg/L) Predict 30-day Mortality in patients with Lower Respiratory Tract Infections Caused by Multidrug and Extensively Drug Resistant Pseudomonas aeruginosa Treated with Ceftolozane/Tazobactam
- (2019) O Rodríguez-Núñez et al. Open Forum Infectious Diseases
- 2286. Evaluating the Impact of Ceftolozane/Tazobactam on Clinical Outcomes in Patients with Multi-Drug-resistant Pseudomonas aeruginosa Pneumonia
- (2019) Matthew Mills et al. Open Forum Infectious Diseases
- Ceftolozane Pharmacokinetics in a Septic Critically Ill Patient under Different Extracorporeal Replacement Therapies
- (2019) Nieves Carbonell et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftolozane–tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa pneumonia in a patient receiving intermittent hemodialysis
- (2018) Mohammed A. Alessa et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Ceftolozane-tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients
- (2018) Morgan Hakki et al. INFECTION
- Ceftolozane/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections
- (2018) Laura Escolà-Vergé et al. INFECTION
- Ceftolozane/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa : clinical and microbiological outcomes
- (2018) B. Dietl et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Evidence of clinical response and stability of Ceftolozane/Tazobactam used to treat a carbapenem-resistant Pseudomonas Aeruginosa lung abscess on an outpatient antimicrobial program
- (2018) A. Stewart et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Clinical experience with ceftolozane/tazobactam in patients with serious infections due to resistant Pseudomonas aeruginosa
- (2018) Marc Xipell et al. Journal of Global Antimicrobial Resistance
- Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands
- (2018) Manuel Díaz-Cañestro et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- A systematic review of the association between delayed appropriate therapy and mortality among patients hospitalized with infections due to Klebsiella pneumoniae or Escherichia coli: how long is too long?
- (2018) Thomas P. Lodise et al. BMC INFECTIOUS DISEASES
- Ceftolozane/tazobactam for the treatment of serious P. aeruginosa infections: a multicenter nationwide clinical experience
- (2018) Matteo Bassetti et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Study
- (2018) Jason C Gallagher et al. Open Forum Infectious Diseases
- Impact of Delayed Appropriate Antibiotic Therapy on Patient Outcomes by Antibiotic Resistance Status From Serious Gram-negative Bacterial Infections
- (2018) Nicole Gidaya Bonine et al. AMERICAN JOURNAL OF THE MEDICAL SCIENCES
- Successful treatment of three severe MDR or XDR Pseudomonas aeruginosa infections with ceftolozane/tazobactam
- (2017) Marc Xipell et al. Future Microbiology
- Ceftolozane/tazobactam for the treatment of MDR Pseudomonas aeruginosa left ventricular assist device infection as a bridge to heart transplant
- (2017) Maddalena Peghin et al. INFECTION
- Use of ceftolozane/tazobactam as salvage therapy for infections due to extensively drug-resistant Pseudomonas aeruginosa
- (2017) Aurélien Dinh et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Successful treatment of post-surgical osteomyelitis caused by XDR Pseudomonas aeruginosa with ceftolozane/tazobactam monotherapy
- (2017) Ivan Gentile et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Multidrug-resistant Pseudomonas aeruginosa skin and soft-tissue infection successfully treated with ceftolozane/tazobactam
- (2017) Nadia Castaldo et al. Journal of Global Antimicrobial Resistance
- Systematic review finds that study data not published in full text articles have unclear impact on meta-analyses results in medical research
- (2017) Christine M. Schmucker et al. PLoS One
- Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections
- (2016) Juan José Castón et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam
- (2016) Alberto Hernández-Tejedor et al. INFECTION
- Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014
- (2016) Lindsey M. Weiner et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration
- (2016) Joseph L. Kuti et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-ResistantPseudomonas aeruginosa
- (2016) Stephen B. Vickery et al. PHARMACOTHERAPY
- Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-ResistantPseudomonas aeruginosa: Table 1.
- (2015) Michael S. Gelfand et al. CLINICAL INFECTIOUS DISEASES
- Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)
- (2015) Joseph Solomkin et al. CLINICAL INFECTIOUS DISEASES
- A review on colistin nephrotoxicity
- (2015) Atefeh Ordooei Javan et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Resistance patterns and outcomes in intensive care unit (ICU)-acquired pneumonia. Validation of European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) classification of multidrug resistant organisms
- (2015) Ignacio Martin-Loeches et al. JOURNAL OF INFECTION
- Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)
- (2015) Florian M Wagenlehner et al. LANCET
- Risk Factors of Carbapenem-Resistant Klebsiella pneumoniae Infection: A Serious Threat in ICUs
- (2015) Yeşim Taşova MEDICAL SCIENCE MONITOR
- Combating Antimicrobial Resistance: Policy Recommendations to Save Lives
- (2011) CLINICAL INFECTIOUS DISEASES
- Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity
- (2011) M. L. Avent et al. INTERNAL MEDICINE JOURNAL
- Hospital-Acquired Infections Due to Gram-Negative Bacteria
- (2010) Anton Y. Peleg et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search